All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Gilles SallesAt this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium. Here, the Lymphoma Hub Chair, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discussed the highlights from the symposium.
Highlights of the Lymphoma Hub Satellite Symposium
The symposium brought together a panel of international experts to discuss the management and treatment of patients with relapsed/refractory (R/R) lymphoma. During the symposium, Kieron Dunleavy and Marie José Kersten discussed the progress being made in the field of R/R diffuse large B-cell lymphoma (DLBCL), while Astrid Pavlovsky and Francesc Bosch discussed how they would treat a patient with R/R chronic lymphocytic leukemia (CLL).
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?